Key Points
- Director sale: Bertram Scott sold 953 BDX shares at an average of $182.61 for about $174,027, trimming his stake by 2.53% to 36,763 shares (≈$6.71M).
- Earnings and guidance: BDX beat quarterly estimates with $2.91 EPS (vs. $2.81 expected) and $5.25B revenue (vs. $5.15B), and set FY2026 guidance of $12.35–$12.65 EPS while analysts expect $14.43 for the current year.
- Capital return actions: The company declared a $1.05 quarterly dividend (annualized $4.20, ~2.3% yield; ex-dividend March 10) and authorized a $10 million share repurchase plan.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) Director Bertram Scott sold 953 shares of the business's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director directly owned 36,763 shares of the company's stock, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Becton, Dickinson and Company Trading Up 3.1%
NYSE BDX opened at $182.82 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The business has a 50 day simple moving average of $198.01 and a 200 day simple moving average of $192.26. The stock has a market capitalization of $52.06 billion, a P/E ratio of 29.82, a P/E/G ratio of 2.32 and a beta of 0.25. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $185.02.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter last year, the company posted $3.43 EPS. The company's revenue for the quarter was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. Becton, Dickinson and Company's dividend payout ratio is presently 68.52%.
Becton, Dickinson and Company announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's management believes its shares are undervalued.
Analyst Upgrades and Downgrades
A number of analysts recently commented on BDX shares. Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an "overweight" rating in a report on Tuesday, December 2nd. Jefferies Financial Group decreased their price objective on Becton, Dickinson and Company from $220.00 to $190.00 and set a "buy" rating for the company in a report on Tuesday, February 10th. Wells Fargo & Company dropped their price target on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 10th. Citigroup decreased their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a "buy" rating for the company in a research report on Tuesday, February 10th. Finally, Stifel Nicolaus boosted their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a "buy" rating in a research note on Wednesday, January 7th. Five equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of "Hold" and an average price target of $195.46.
Check Out Our Latest Research Report on BDX
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Activest Wealth Management boosted its stake in shares of Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 97 shares during the last quarter. Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the third quarter valued at about $25,000. SOA Wealth Advisors LLC. boosted its holdings in Becton, Dickinson and Company by 256.8% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 95 shares during the period. Steph & Co. raised its position in shares of Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier's stock valued at $26,000 after buying an additional 65 shares in the last quarter. Finally, Prosperity Bancshares Inc bought a new position in shares of Becton, Dickinson and Company in the fourth quarter worth about $29,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.
Becton, Dickinson and Company Company Profile
(
Get Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
